<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04634578</url>
  </required_header>
  <id_info>
    <org_study_id>ROP4</org_study_id>
    <secondary_id>UG1EY011751</secondary_id>
    <nct_id>NCT04634578</nct_id>
  </id_info>
  <brief_title>Bevacizumab Treatment For Posterior Zone I ROP</brief_title>
  <acronym>ROP4</acronym>
  <official_title>Bevacizumab Treatment For Posterior Zone I Retinopathy of Prematurity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pediatric Eye Disease Investigator Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 1 retinopathy of prematurity in zone I represents the most severe type of ROP and has&#xD;
      the worst prognosis. It is unknown whether low-dose bevacizumab will be successful in these&#xD;
      severe cases. Also unknown is the timing and extent of peripheral retinal vascularization&#xD;
      after low-dose bevacizumab compared with the standard dose. The current study will evaluate&#xD;
      whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and&#xD;
      retinal vessels all in zone I.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infants with type 1 ROP and no prior treatment for ROP will be randomly assigned (1:1) to&#xD;
      treatment with either intravitreous bevacizumab 0.063 mg or either intravitreous bevacizumab&#xD;
      0.25 mg. Study exams will be at 1 day, 4 days (if no improvement on day 1), 1, 2, 3, and 4&#xD;
      weeks, and at 2 and 4-months post-treatment (and re-treatment when indicated). Additional&#xD;
      study exams will occur at adjusted age 6 and 12 months. Non-study examinations will be at&#xD;
      clinician discretion and are likely to occur more often. The primary outcome will be&#xD;
      treatment success within each dose group, defined as improvement by the day 4 exam and no&#xD;
      recurrence of type 1 ROP or severe neovascularization requiring additional treatment within 4&#xD;
      weeks of injection. Important secondary outcomes include safety and efficacy. refractive&#xD;
      outcomes, and the extent of retinal vascularization at 2 and 4 months post-injection between&#xD;
      the two dose groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Success at 4 Weeks Post Injection</measure>
    <time_frame>4 weeks</time_frame>
    <description>Treatment success, determined at 4 weeks, post injection, and meeting all the following criteria:&#xD;
Improvement by the 4-day exam (3 to 5 days)&#xD;
No recurrence of type 1 ROP or severe neovascularization requiring additional treatment within 4 weeks of injection.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Retinopathy of Prematurity</condition>
  <arm_group>
    <arm_group_label>Bevacizumab- 0.063 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single intravitreal injection of 0.063 mg of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevacizumab- 0.25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single intravitreal injection of 0.25 mg of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>All participants will receive a single intravitreal injection of bevacizumab in one or both eyes following enrollment into the study. The injection/s should be given as soon as possible but no later than 2 days after the diagnosis of type 1 ROP meeting all of the inclusion criteria and none of the exclusion criteria.&#xD;
Eyes meeting eligibility criteria will receive a single dose of 0.063 mg or 0.25mg bevacizumab provided by the pharmacy at the investigator's institution.</description>
    <arm_group_label>Bevacizumab- 0.063 mg</arm_group_label>
    <arm_group_label>Bevacizumab- 0.25 mg</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The study participant must have at least one eye meeting all of the inclusion criteria in&#xD;
        order to be eligible to participate:&#xD;
&#xD;
          1. Birth weight &lt; 1251 grams&#xD;
&#xD;
          2. Newly diagnosed (within 2 days) type 1 ROP (as defined in section 2.4.2), with ROP and&#xD;
             retinal vessels all in zone I, in one or both eyes&#xD;
&#xD;
          3. Parent understands the protocol and is willing to provide consent.&#xD;
&#xD;
        If both eyes are eligible, then both are included. If one eye is eligible and the other eye&#xD;
        has type 1 ROP with ROP or vessels in zone 2, then both eyes will receive the treatment&#xD;
        randomly assigned. If one eye is eligible and the fellow eye later develops type 1 ROP&#xD;
        within 4 weeks of injection in the first eye, then the fellow eye will also receive the&#xD;
        treatment randomly assigned to the first eye and the fellow eye will follow the same 4-week&#xD;
        post-injection study exam schedule, unless the first eye has already met failure criteria,&#xD;
        in which case treatment and follow-up for the fellow eye is at investigator discretion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants meeting any of the following exclusion criteria will be excluded from study&#xD;
        participation.&#xD;
&#xD;
          1. Previous treatment for ROP&#xD;
&#xD;
          2. Stage 4 or 5 ROP in either eye&#xD;
&#xD;
          3. Treatment could not be done within 2 days of diagnosis of type 1 ROP&#xD;
&#xD;
          4. Investigator unwilling to randomize or parent unwilling to accept randomized&#xD;
             assignment to either treatment&#xD;
&#xD;
          5. Transfer to another hospital anticipated within the next 4 weeks where exams by&#xD;
             study-certified examiners are not available. If hospital discharge is anticipated&#xD;
             within the next 4 weeks, parents unable or unwilling to return to the PEDIG site for&#xD;
             outpatient follow-up visits.&#xD;
&#xD;
          6. Active ocular infection or purulent nasolacrimal duct obstruction in either eye&#xD;
&#xD;
        One eye will be excluded, and other eye may be eligible, if either of the following are&#xD;
        present:&#xD;
&#xD;
          -  Visually significant ocular anomaly (e.g., cataract, coloboma)&#xD;
&#xD;
          -  Opacity that precludes an adequate view of the retina&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>6 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David K Wallace, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raymond T Kraker, MSPH</last_name>
    <phone>8139758690</phone>
    <email>rkraker@jaeb.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brooke P Fimbel</last_name>
    <phone>8139758690</phone>
    <email>bfimbel@jaeb.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arkansas Childrens Hospital/ University of Arkansas Medical Sciences</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Florin Grigorian, MD</last_name>
      <phone>501-364-4125</phone>
      <email>fgrigorian@uams.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univ of California, Irvine- Gavin Herbert Eye Institute</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donny Suh, MD, MBA</last_name>
      <phone>949-824-9089</phone>
      <email>dowsuh@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jules Stein Eye Institute at the University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy L Pineles, MD</last_name>
      <phone>310-825-2872</phone>
      <email>pineles@jsei.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcela M Estrada, MD</last_name>
      <phone>916-734-8755</phone>
      <email>mmestrada@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco Department of Ophthalmology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandra de Alba Campomanes, MD</last_name>
      <phone>415-353-2560</phone>
      <email>dealbaa@vision.ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Denver Health and Hospital Authority</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesse M Smith, MD</last_name>
      <phone>303-436-6000</phone>
      <email>jesse.smith@dhha.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Connecticut Childrens Medical Center</name>
      <address>
        <city>Farmington</city>
        <state>Connecticut</state>
        <zip>06032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janine E Collinge, MD</last_name>
      <phone>860-837-9600</phone>
      <email>jcollinge@connecticutchildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Emory Eye Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Hutchinson, MD</last_name>
      <phone>404-778-4725</phone>
      <email>amy.hutchinson@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>U of Illinois at Chicago Eye and Ear Infirmary</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel E Maidana, MD, PhD</last_name>
      <email>maidana@uic.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Hyde Park</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah H Rodriguez</last_name>
      <phone>773-702-3937</phone>
      <email>srodriguez5@bad.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David K Wallace, MD, MPH</last_name>
      <phone>317-278-2651</phone>
      <email>dwallac@iu.edu</email>
    </contact>
    <investigator>
      <last_name>David K Wallace, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Haider, MD</last_name>
      <phone>317-274-1214</phone>
      <email>khaider@iupui.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UK Ophthalmology and Visual Sciences, The Eye Clinic</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John M Franklin, MD</last_name>
      <phone>859-323-5868</phone>
      <email>john.franklin@uky.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Greater Baltimore Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204-5809</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison A Jensen, MD</last_name>
      <phone>443-849-6341</phone>
      <email>ajensen@gbmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolyn Wu, MD</last_name>
      <email>carolyn.wu@childrens.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Missouri- Columbia Mason Eye Institute</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed M Elkeeb, MD</last_name>
      <phone>573-875-9000</phone>
      <email>elkeeba@health.missouri.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Louis University Ophthalmology</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bradley V Davitt, MD</last_name>
      <phone>314-977-4931</phone>
      <email>davittb@slu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian David H Koch Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anton Orlin, MD</last_name>
      <phone>646-697-6428</phone>
      <email>ano9028@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Go, MD</last_name>
      <phone>919-966-5296</phone>
      <email>michelle_go@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon F Freedman, MD</last_name>
      <phone>919-684-2038</phone>
      <email>Freed003@mc.duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Yang, MD</last_name>
      <phone>513-636-4751</phone>
      <email>Michael.Yang@cchmc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pediatric Ophthalmology Associates, Inc.</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine O Jordan, MD</last_name>
      <phone>614-224-6222</phone>
      <email>cateolsonjordan@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Campbell</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne K Jensen, MD</last_name>
      <email>anne.kelso.jensen@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Eye Center of Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ken Nischal, MD</last_name>
      <phone>412-692-5918</phone>
      <email>nischalkk@upmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Storm Eye Institute</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Bowsher</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital - Dept. Of Ophthalmology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amit Bhatt, MD</last_name>
      <phone>832-822-3230</phone>
      <email>arbhatt@texaschildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Woman's Hospital of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charity H Grannis, MD</last_name>
      <phone>713-790-1234</phone>
      <email>cgrannis@houstoneye.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79424</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Shami, MD</last_name>
      <phone>806-792-0066</phone>
      <email>ysaldivar@texasretina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Utah Moran Eye Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Elizabeth Hartnett, MD</last_name>
      <phone>801-581-2352</phone>
      <email>ME.Hartnett@hsc.utah.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Virginia Pediatric Eye Center</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Crouch, MD</last_name>
      <phone>757-461-0050</phone>
      <email>ercrouch@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Surrey Memorial Hospital</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Gizicki, MD</last_name>
      <phone>604-581-2211</phone>
      <email>r.gizicki@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IWK Health Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3K 6R8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johane M Robitaille, MD</last_name>
      <phone>902-470-8731</phone>
      <email>jrobitai@dal.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masrin Najm-Tehran, MD</last_name>
      <phone>416-813-7654</phone>
      <phone_ext>201401</phone_ext>
      <email>nasrin.tehrani@sickkids.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU - Sainte-Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosanne Superstein, MD</last_name>
      <phone>514-345-4715</phone>
      <email>rosanne.superstein@mcgill.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pedig.net</url>
    <description>PEDIG Public Website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2020</study_first_submitted>
  <study_first_submitted_qc>November 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinopathy of Prematurity</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the Pediatric Eye Disease Investigator Group (PEDIG) public website after the completion of each protocol and publication of the primary manuscript.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data will be made available after publication of each primary manuscript.</ipd_time_frame>
    <ipd_access_criteria>Users accessing the data must enter an email address.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 21, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT04634578/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 5, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT04634578/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 24, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT04634578/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

